EMN 2021 | Real-world data: KRd in R/R multiple myeloma
Elena Zamagni, MD, PhD, University of Bologna, Bologna, Italy, summarises the key findings from a real-world analysis of carfilzomib plus lenalidomide and dexamethasone (KRd) in patients with relapsed/refractory (R/R) multiple myeloma. The study found that efficacy results were reproducible in a real-world setting and tolerability was high. Dr Zamagni reports that KRd is a good option for post-relapse treatment of patients with multiple myeloma, who have not previously received lenalidomide. This interview took place during the 2021 European Myeloma Network (EMN) congress.
Transcript (edited for clarity)
Carfilzomib combined with lenalidomide and dexamethasone has been one of the first triplet used in the relapsed/refractory setting of multiple myeloma. After this schema, of course, several other combination became available, so nowadays we can use lenalidomide combined with monoclonal antibodies or with the oral proteasome inhibitors. However, many hematologists do have a lot of experience with this combination, carfilzomib-len-dex that is also used sometimes to re-induce a remission during the first relapse prior and after to a salvage autologous stem cell transplantation...
Carfilzomib combined with lenalidomide and dexamethasone has been one of the first triplet used in the relapsed/refractory setting of multiple myeloma. After this schema, of course, several other combination became available, so nowadays we can use lenalidomide combined with monoclonal antibodies or with the oral proteasome inhibitors. However, many hematologists do have a lot of experience with this combination, carfilzomib-len-dex that is also used sometimes to re-induce a remission during the first relapse prior and after to a salvage autologous stem cell transplantation.
So, what we did was to look in real life, which were the results of this combination, if the results of the clinical trials were reproducible, and also how was the tolerability of this triplet when you are facing, of course, a real life, so patients that are not perfectly matching all the inclusion criteria that are usually required in clinical trials. So, we were able to see that, in fact, the results in terms of efficacy were reproduced and that the combination is highly tolerable in real life.
So, KRd continues to be a good option for patients to be treated at or during the relapse phase. Of course, many of our patients nowadays are using lenalidomide upfront in the first line, so of course, this triplet is not of course the best option when you already used lenalidomide. However, we do still have patients lenalidomide-free and for sure this combination may be of help.
Read more...
Disclosures
Elena Zamagni, MD, PhD, has received honoraria from, and participated in advisory boards for Amgen, Sanofi, BMS, Takeda, Janssen, Oncopeptides and Karyopharm.
